Edgar Filing: Fridriksdottir Hafrun

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Fridriksdottir Hafrun

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2018

3. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.,Â 5 BASEL STREET

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Executive VP, Global R&D

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

PETACH TIKVA,Â L3Â 4951033

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	3,346	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (right to buy)	Â ⁽²⁾	06/30/2024	Ordinary Shares ⁽¹⁾	22,809	$ 48.69	D	Â
Stock Options (right to buy)	Â ⁽³⁾	08/01/2026	Ordinary Shares ⁽¹⁾	15,990	$ 52.96	D	Â
Stock Options (right to buy)	Â ⁽⁴⁾	09/08/2026	Ordinary Shares ⁽¹⁾	5,553	$ 50.21	D	Â
Stock Options (right to buy)	Â ⁽⁵⁾	11/30/2026	Ordinary Shares ⁽¹⁾	57,167	$ 37.7	D	Â
Stock Options (right to buy)	Â ⁽⁶⁾	02/14/2027	Ordinary Shares ⁽¹⁾	85,042	$ 34.9	D	Â
Restricted Share Units	Â ⁽⁷⁾	Â ⁽⁷⁾	Ordinary Shares ⁽¹⁾	3,432	$ ⁽⁸⁾	D	Â
Restricted Share Units	Â ⁽⁹⁾	Â ⁽⁹⁾	Ordinary Shares ⁽¹⁾	9,280	$ ⁽⁸⁾	D	Â
Restricted Share Units	Â ⁽¹⁰⁾	Â ⁽¹⁰⁾	Ordinary Shares ⁽¹⁾	2,330	$ ⁽⁸⁾	D	Â
Restricted Share Units	Â ⁽¹¹⁾	Â ⁽¹¹⁾	Ordinary Shares ⁽¹⁾	2,242	$ ⁽⁸⁾	D	Â
Restricted Share Units	Â ⁽¹²⁾	Â ⁽¹²⁾	Ordinary Shares ⁽¹⁾	796	$ ⁽⁸⁾	D	Â
Restricted Share Units	Â ⁽¹³⁾	Â ⁽¹³⁾	Ordinary Shares ⁽¹⁾	10,844	$ ⁽⁸⁾	D	Â
Restricted Share Units	Â ⁽¹⁴⁾	Â ⁽¹⁴⁾	Ordinary Shares ⁽¹⁾	16,061	$ ⁽⁸⁾	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Fridriksdottir Hafrun C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA,Â L3Â 4951033	Â	Â	Â Executive VP, Global R&D	Â

Signatures

/s/ Dov Bergwerk, as attorney-in-fact for Hafrun Fridriksdottir		01/02/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)	Stock options were granted on July 1, 2014, with 7,603 having vested on July 1, 2017 and 7,603 vesting on each of July 1, 2018 and July 1, 2019.
(3)	Stock options were granted on August 2, 2016, with 3,997 having vested on August 2, 2017, 3,997 vesting on each of March 17, 2018 and March 17, 2019 and 3,999 vesting on March 17, 2020.
(4)	Stock options were granted on September 9, 2016, with 1,388 having vested on September 9, 2017, 1,388 vesting on each of March 17, 2018 and March 17, 2019 and 1,389 vesting on March 17, 2020.
(5)	Stock options were granted on November 30, 2016, with 14,292 vesting on November 30, 2018 and 42,875 vesting on November 30, 2019.
(6)	Stock options were granted on February 14, 2017, with 28,347 vesting on each of February 14, 2019 and February 14, 2020 and 28,348 vesting on February 14, 2021.
(7)	Restricted share units were granted on May 8, 2014 and vest on March 5, 2018.
(8)	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
(9)	Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019.
(10)	Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.
(11)	Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.
(12)	Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.
(13)	Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.
(14)	Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.
Â Remarks: TheÂ ReportingÂ PersonÂ isÂ filingÂ thisÂ formÂ inÂ connectionÂ withÂ theÂ Issuer'sÂ transitionÂ fromÂ aÂ foreignÂ privateÂ issuerÂ toÂ aÂ domesticÂ issuer,Â effectiveÂ JanuaryÂ 1,Â 2018. ExhibitÂ List Â Â Â Â Â ExhibitÂ 24Â -Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.